# Altimmune Inc. (ALT) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $2.04, market value $397 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Altimmune Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 9678.4×**. Each dollar of revenue is priced at 9678.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 0.8×**. The shares trade below book value, which can signal a bargain or a balance sheet the market doubts.
- **Free-cash-flow yield: -19.3%** (5-yr avg -16.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -39.2%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -43.5%**. Return on all capital, debt included, is -43.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -31.5%**. Each dollar of assets produces -31.5% of profit.

## Growth
- **Revenue growth (1 yr): 105.0%** (5-yr -65.3%/yr). Revenue grew 105.0% over the last year, against -65.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 25.4%**. Earnings per share rose 25.4%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.15**. Debt is 0.15 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.1×**. It would take 0.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: -57.8×**. Operating profit covers interest only -57.8×: fragile.
- **Current ratio: 18.55** (quick 18.55). Current assets cover the next year's liabilities 18.55 times.
- **Altman Z-score: 5.47**. A Z-score of 5.47 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Altimmune Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -50.1%** (YTD -44.0%, 3-mo -32.7%). The shares are down 50.1% over twelve months including dividends.
- **From 52-week high: -68.3%** (2.5% above the low). Trading 68% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 26**. An RSI of 26 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 1.56** (volatility 69%). Beta of 1.56 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ALT · Page: https://foliofundamentals.com/stocks/alt

Not investment advice.